Trial ID or NCT#

NCT00600886

Status

NOT RECRUITING

Purpose

The patients will receive either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study is to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) between the two treatment groups (pasireotide LAR and octreotide LAR) at 12 months. Following one year of treatment patients may proceed into the study extension. Patients who did not respond to the treatment they were randomized to (based on month 12 assessment results) will be switched to the other treatment arm at month 13.

Official Title

A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Laurence Katznelson, MD
Neuroendocrinologist
Professor of Neurosurgery and of Medicine (Endocrinology) at the Stanford University Medical Center, Lucile Salter Packard Children's Hospital and at the Palo Alto Veterans Affairs Health Care System

Contact us to find out if this trial is right for you.

CONTACT

Jacob Petralia
(650) 721-2830